X0306 4 2019-07-29 0 0001466301 Clovis Oncology, Inc. CLVS 0000935463 KLINGENSTEIN PAUL H C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 1 0 0 0 Common Stock 2019-07-29 4 M 0 25862 0.29 A 59327 D Common Stock 639078 I By Aberdare Ventures IV, L.P. Common Stock 12755 I By Aberdare Partners IV, L.P. Stock Option (right to buy) 0.29 2019-07-29 4 M 0 25862 0.00 D 2019-08-26 Common Stock 25862 0 D Includes shares previously reported as indirectly owned through Aberdare Ventures IV, L.P. ("Aberdare Ventures IV") and Aberdare Partners IV, L.P. ("Aberdare Partners IV"), which shares were received by the Reporting Person pursuant to distributions in kind effected by such entities. These distributions constituted a change in form of ownership from indirect to direct and, accordingly, were not required to be reported pursuant to Section 16. Gives effect to the reduction in shares held by virtue of the distributions in kind described in footnote (1). The Reporting Person is a Managing Director of Aberdare GP IV, L.L.C. ("Aberdare GP IV"), which serves as the sole General Partner of Aberdare Ventures IV and Aberdare Partners IV. As such, the Reporting Person shares voting and investment control over the securities owned by Aberdare Ventures IV and Aberdare Partners IV, and may be deemed to own beneficially the securities held by Aberdare Ventures IV and Aberdare Partners IV. Aberdare GP IV owns no securities of the Issuer directly. The Reporting Person disclaims beneficial ownership of the shares held by Aberdare Ventures IV and Aberdare Partners IV except to the extent of his proportionate pecuniary interest therein. The option was immediately exercisable as to both vested and unvested shares. 25% of the shares subject to the option vested on each of August 26, 2009, August 26, 2010, August 26, 2011 and August 26, 2012. /s/ Paul H. Klingenstein 2019-07-30